Patents by Inventor Jurg Tschopp

Jurg Tschopp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF MODULATING IMMUNE RESPONSES USING BCMA POLYPEPTIDE
    Publication number: 20200095305
    Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.
    Type: Application
    Filed: October 16, 2019
    Publication date: March 26, 2020
    Applicants: Biogen MA Inc., Topotarget Switzerland SA
    Inventors: Jeffrey Browning, Christine Ambrose, Fabienne MacKay, Jurg Tschopp, Pascal Schneider, Jeffrey Thompson
  • Methods of modulating immune responses using BCMA polypeptide
    Patent number: 10494416
    Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: December 3, 2019
    Assignees: Biogen MA Inc., Topotarget Switzerland SA
    Inventors: Jeffrey Browning, Christine Ambrose, Fabienne MacKay, Jurg Tschopp, Pascal Schneider, Jeffrey Thompson
  • METHODS OF MODULATING IMMUNE RESPONSES USING BCMA POLYPEPTIDE
    Publication number: 20180273605
    Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.
    Type: Application
    Filed: May 15, 2017
    Publication date: September 27, 2018
    Applicants: Biogen MA Inc., Topotarget Switzerland SA
    Inventors: Jeffrey Browning, Christine Ambrose, Fabienne MacKay, Jurg Tschopp, Pascal Schneider, Jeffrey Thompson
  • Methods of treating autoimmune diseases using a B-cell maturation antigen (BCMA)
    Patent number: 9650430
    Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: May 16, 2017
    Assignee: BIOGEN, MA INC.
    Inventors: Jeffrey Browning, Christine Ambrose, Fabienne MacKay, Jurg Tschopp, Pascal Schneider, Jeffrey Thompson
  • BAFF RECEPTOR (BCMA), AN IMMUNOREGULATORY AGENT
    Publication number: 20150139992
    Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.
    Type: Application
    Filed: August 6, 2014
    Publication date: May 21, 2015
    Applicants: TOPOTARGET SWITZERLAND SA, BIOGEN IDEC MA INC.
    Inventors: Jeffrey Browning, Christine Ambrose, Fabienne MacKay, Jurg Tschopp, Pascal Schneider, Jeffrey Thompson
  • FUSION CONSTRUCTS CONTAINING ACTIVE SECTIONS OF TNF LIGANDS
    Publication number: 20150098944
    Abstract: Disclosed is a recombinant fusion protein containing an amino-acid sequence which comprises: (a) the Fc section or part of an Fc section of an immunoglobulin as component (A) or a functional variant of component (A); (b) the extracellular part of a TNF ligand or a partial sequence of the extracellular part of a TNF ligand as component (B) or a functional variant of component (B); and optionally (c) a transition area between component (A) and component (B), containing a linker.
    Type: Application
    Filed: October 23, 2014
    Publication date: April 9, 2015
    Inventors: Olivier Gaide, Pascal Schneider, Jurg Tschopp
  • BIMER OR AN OLIGOMER OF A DIMER, TRIMER, QUADROMER OR PENTAMER OF RECOMBINANT FUSION PROTEINS
    Publication number: 20150004129
    Abstract: The invention relates to oligomers of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins. The oligomers are characterized in that the recombinant fusion proteins have at least one component A and at least one component B, whereby component A contains a protein or a protein segment with a biological function, in particular with a ligand function for antibodies, for soluble or membranous signal molecules, for receptors or an antibody, or an antibody segment, and component B contains a protein or a protein segment which dimerizes or oligomerizes the dimer, trimer, quatromer or pentamer of the recombinant fusion protein, without the action of third-party molecules. The invention also relates to the use of dimers or oligomers of this type for producing a medicament, to the fusion proteins which cluster in dimers or oligomers and to their DNA sequence and expression vectors or host cells comprising this DNA sequence.
    Type: Application
    Filed: April 29, 2014
    Publication date: January 1, 2015
    Applicant: TOPOTARGET SWITZERLAND SA
    Inventors: Jurg TSCHOPP, Pascal SCHNEIDER, Nils HOLLER
  • Pharmaceutical composition comprising EDA-1 Fusion Protein
    Patent number: 8895003
    Abstract: Disclosed is a recombinant fusion protein containing an amino-acid sequence which comprises: (a) the Fc section or part of an Fc section of an immunoglobulin as component (A) or a functional variant of component (A); (b) the extracellular part of a TNF ligand or a partial sequence of the extracellular part of a TNF ligand as component (B) or a functional variant of component (B); and optionally (c) a transition area between component (A) and component (B), containing a linker.
    Type: Grant
    Filed: June 20, 2013
    Date of Patent: November 25, 2014
    Assignee: Topotarget Switzerland SA
    Inventors: Olivier Gaide, Pascal Schneider, Jurg Tschopp
  • Methods of screening for a compound that inhibits the interaction between BAFF and BCMA
    Patent number: 8828669
    Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.
    Type: Grant
    Filed: February 21, 2012
    Date of Patent: September 9, 2014
    Assignee: Biogen Idec MA Inc.
    Inventors: Jeffrey Browning, Christine Ambrose, Fabienne MacKay, Jurg Tschopp, Pascal Schneider, Jeffrey Thompson
  • METHODS AND MEDICAMENTS FOR THE TREATMENT OF GOUT OR PSEUDOGOUT
    Publication number: 20130302344
    Abstract: The present invention relates to a new method, and the process to manufacture a medicament, for treating gout or pseudogout, comprising administering an effective amount of inhibitors blocking IL-1 or its maturation by the NALP3 inflammasome.
    Type: Application
    Filed: July 16, 2013
    Publication date: November 14, 2013
    Inventors: Virginie Petrilli, Fabio Martinon, Jurg Tschopp, Thibault De Smedt
  • FUSION CONSTRUCTS CONTAINING ACTIVE SECTIONS OF TNF LIGANDS
    Publication number: 20130295093
    Abstract: Disclosed is a recombinant fusion protein containing an amino-acid sequence which comprises: (a) the Fc section or part of an Fc section of an immunoglobulin as component (A) or a functional variant of component (A); (b) the extracellular part of a TNF ligand or a partial sequence of the extracellular part of a TNF ligand as component (B) or a functional variant of component (B); and optionally (c) a transition area between component (A) and component (B), containing a linker.
    Type: Application
    Filed: June 20, 2013
    Publication date: November 7, 2013
    Inventors: Olivier GAIDE, Pascal SCHNEIDER, Jurg Tschopp
  • Treatment of ectodermal dysplasia with EDA1 fusion proteins
    Patent number: 8501177
    Abstract: Disclosed is a recombinant fusion protein containing an amino-acid sequence which comprises: (a) the Fc section or part of an Fc section of an immunoglobulin as component (A) or a functional variant of component (A); (b) the extracellular part of a TNF ligand or a partial sequence of the extracellular part of a TNF ligand as component (B) or a functional variant of component (B); and optionally (c) a transition area between component (A) and component (B), containing a linker.
    Type: Grant
    Filed: April 8, 2010
    Date of Patent: August 6, 2013
    Assignee: Topotarget Switzerland SA
    Inventors: Olivier Gaide, Pascal Schneider, Jurg Tschopp
  • BIMER OR AN OLIGOMER OF A DIMER, TRIMER, QUADROMER OR PENTAMER OF RECOMBINANT FUSION PROTEINS
    Publication number: 20120009211
    Abstract: The invention relates to oligomers of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins. Said oligomers are characterized in that the recombinant fusion proteins have at least one component A and at least one component B, whereby component A contains a protein or a protein segment with a biological function, in particular with a ligand function for antibodies, for soluble or membranous signal molecules, for receptors or an antibody, or an antibody segment, and component B contains a protein or a protein segment which dimerizes or oligomerizes the dimer, trimer, quatromer or pentamer of the recombinant fusion protein, without the action of third-party molecules. The invention also relates to the use of dimers or oligomers of this type for producing a medicament, to the fusion proteins which cluster in dimers or oligomers and to their DNA sequence and expression vectors or host cells comprising this DNA sequence.
    Type: Application
    Filed: March 31, 2011
    Publication date: January 12, 2012
    Applicant: TOPOTARGET SWITZERLAND SA
    Inventors: JÜRG TSCHOPP, PASCAL SCHNEIDER, NILS HOLLER
  • METHOD FOR THE TREATMENT OF GOUT OR PSEUDOGOUT
    Publication number: 20110262449
    Abstract: The present invention relates to a new method, and the process to manufacture a medicament, for treating gout or pseudogout, comprising administering an effective amount of inhibitors blocking IL-1 or its maturation by the NALP3 inflammasome.
    Type: Application
    Filed: July 1, 2011
    Publication date: October 27, 2011
    Applicant: TOPOTARGET SWITZERLAND SA
    Inventors: Virginie PETRILLI, Fabio Martinon, Jurg Tschopp, Thibault De Smedt
  • Train-R: A Cysteine Rich Member of the TNF-Receptor Family
    Publication number: 20110158993
    Abstract: Novel receptor in the TNF family: TRAIN-receptor.
    Type: Application
    Filed: November 22, 2010
    Publication date: June 30, 2011
    Applicants: Biogen Idec MA Inc., Apoxis S.A.
    Inventors: Jurg Tschopp, Catherine Hession
  • Antibodies to train R: a cysteine-rich member of the TNF-receptor family, and methods of treating tumors expressing said receptor
    Patent number: 7838639
    Abstract: Embodiments of the present invention encompass novel receptors of the TNF family. In particular, embodiments of the invention encompass TNF Receptor in the BRAIN (TRAIN) and isolated antibodies that bind to the same. In some embodiments, isolated antibodies that bind to TRAIN are useful in regulating cell differentiation, death, and survival. Other embodiments of the invention encompass pharmaceutical compositions comprising antibodies that bind to human TRAIN.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: November 23, 2010
    Assignees: Biogen Idec MA Inc., Apoxis S.A.
    Inventors: Jurg Tschopp, Catherine Hession
  • FUSION CONSTRUCTS CONTAINING ACTIVE SECTIONS OF TNF LIGANDS
    Publication number: 20100254984
    Abstract: Disclosed is a recombinant fusion protein containing an amino-acid sequence which comprises: (a) the Fc section or part of an Fc section of an immunoglobulin as component (A) or a functional variant of component (A); (b) the extracellular part of a TNF ligand or a partial sequence of the extracellular part of a TNF ligand as component (B) or a functional variant of component (B); and optionally (c) a transition area between component (A) and component (B), containing a linker.
    Type: Application
    Filed: April 8, 2010
    Publication date: October 7, 2010
    Applicant: APOXIS S.A.
    Inventors: Olivier Gaide, Pascal Schneider, Jurg Tschopp
  • BAFF, inhibitors thereof and their use in the modulation of B-cell response
    Publication number: 20100233179
    Abstract: The invention provides methods for treating or preventing disorders associated with expression of BAFF comprising BAFF and fragments thereof, antibodies, agonists and antagonists.
    Type: Application
    Filed: September 30, 2009
    Publication date: September 16, 2010
    Inventors: Jeffrey Browning, Christine Ambrose, Fabienne MacKay, Jurg Tschopp, Pascal Schneider
  • Fusion constructs containing active sections on TNF ligands
    Patent number: 7736657
    Abstract: Disclosed is a recombinant fusion protein containing an amino-acid sequence which comprises: (a) the Fc section or part of an Fc section of an immunoglobulin as component (A) or a functional variant of component (A); (b) the extracellular part of a TNF ligand or a partial sequence of the extracellular part of a TNF ligand as component (B) or a functional variant of component (B); and optionally (c) a transition area between component (A) and component (B), containing a linker.
    Type: Grant
    Filed: August 21, 2002
    Date of Patent: June 15, 2010
    Assignee: Apoxis S.A.
    Inventors: Olivier Gaide, Pascal Schneider, Jürg Tschopp
  • BIMER OR AN OLIGOMER OF A DIMER, TRIMER, QUATROMER OR PENTAMER OF RECOMBINANT FUSION PROTEINS
    Publication number: 20090053252
    Abstract: The invention relates to oligomers of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins. Said oligomers are characterized in that the recombinant fusion proteins have at least one component A and at least one component B, whereby component A contains a protein or a protein segment with a biological function, in particular with a ligand function for antibodies, for soluble or membranous signal molecules, for receptors or an antibody, or an antibody segment, and component B contains a protein or a protein segment which dimerizes or oligomerizes the dimer, trimer, quatromer or pentamer of the recombinant fusion protein, without the action of third-party molecules. The invention also relates to the use of dimers or oligomers of this type for producing a medicament, to the fusion proteins which cluster in dimers or oligomers and to their DNA sequence and expression vectors or host cells comprising this DNA sequence.
    Type: Application
    Filed: June 2, 2008
    Publication date: February 26, 2009
    Applicant: Apotech Research and Development Ltd.
    Inventors: Jurg Tschopp, Pascal Schneider, Nils Holler